Mechanism for carbapenem resistance of clinical enterobacteriaceae isolates

Experimental and Therapeutic Medicine

Volumn 15, Issue 1, 2018, Pages 1143-1149

  Ye, Yafei ^a   Xu, Lijuan ^a   Han, Yanping ^a   Chen, Zhe ^a   Liu, Cailin ^a   Ming, Liang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Carbapenem resistant enterobacteriaceae; Polymerase chain reaction; SDS PAGE

Indexed keywords

BACTERIAL PROTEIN; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEMASE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; OUTER MEMBRANE PORIN; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DISK DIFFUSION; DRUG SENSITIVITY; ENTEROBACTERIACEAE INFECTION; GENE MUTATION; HUMAN; INHIBITION ZONE; KLEBSIELLA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; QUALITY CONTROL; RECEPTOR DOWN REGULATION;

EID: 85035194003     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2017.5485     Document Type: Article

References (19)

1. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, et al: Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 10: 597-602, 2010.
2. Barbier F, Pommier C, Garrouste-Orgeas M, Schwebel C, Ruckly S, Dumenil AS, Lemiale V, Mourvillier B, Clec'h C, Darmon M, et al: Extended-spectrum beta-lactamase-producing Enterobacteriaceae in critically iii patients: Impact of carriage and infection on carbapenem consumption, duration of Icu stay, and mortality. Intensive Care Med Exp 3 (Suppl 1): A1, 2015.
3. Mushtaq S, Woodford N, Hope R, Adkin R and Livermore DM: Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother 68: 1601-1608, 2013.
4. Nordmann P, Dortet L and Poirel L: Carbapenem resistance in Enterobacteriaceae: Here is the storm! Trends Mol Med 18: 263-272, 2012.
5. Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, Seo SK, Rosenthal ME, Sperber SJ, Jenkins SG, et al: Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 61: pii: e02349-16, 2017.
6. Blair JM, Webber MA, Baylay AJ, Ogbolu DO and Piddock LJ: Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13: 42-51, 2015.
7. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, et al: Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect Dis 16: 161-168, 2016.
8. Khan AU, Maryam L and Zarrilli R: Structure, genetics and worldwide spread of New Delhi metallo-β-lactamase (NDM): A threat to public health. BMC Microbiol 17: 101, 2017.
9. Diene SM and Rolain JM: Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. Clin Microbiol Infect 20: 831-838, 2014.
10. Vasoo S, Barreto JN and Tosh PK: Emerging issues in gram-negative bacterial resistance: An update for the practicing clinician. Mayo Clin Proc 90: 395-403, 2015.
11. Brust K, Evans A and Plemmons R: Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with high-dose tigecycline. J Antimicrob Chemother 69: 2875-2876, 2014.
12. Gupta N, Limbago BM, Patel JB and Kallen AJ: Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 53: 60-67, 2011.
13. Surgers L, Boyd A, Boelle PY, Lalande V, Jolivot PA, Girard PM, Arlet G, Cambier C, Homor A, Decre D and Meynard JL: Clinical and microbiological determinants of severe and fatal outcomes in patients infected with Enterobacteriaceae producing extended-spectrum β-lactamase. Eur J Clin Microbiol Infect Dis 36: 1261-1268, 2017.
14. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C and Leibovici L: Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69: 2305-2309, 2014.
15. Steinmann J, Kaase M, Gatermann S, Popp W, Steinmann E, Damman M, Paul A, Saner F, Buer J and Rath P: Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro Surveill 16: pii: 19944, 2011.
16. Hu F, Chen S, Xu X, Guo Y, Liu Y, Zhu D and Zhang Y: Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China. J Med Microbiol 61: 132-136, 2012.
17. Ho PL, Lo WU, Yeung MK, Lin CH, Chow KH, Ang I, Tong AH, Bao JY, Lok S and Lo JY: Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong. PLoS One 6: e17989, 2011.
18. Yang Q, Wang H, Sun H, Chen H, Xu Y and Chen M: Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: Results from large hospital-based surveillance studies in China. Antimicrob Agents Chemother 54: 573-577, 2010.
19. Lee JY, Hong YK, Lee H and Ko KS: High prevalence of non-clonal imipenem-nonsusceptible Enterobacter spp. isolates in Korea and their association with porin down-regulation. Diagn Microbiol Infect Dis 87: 53-59, 2017.